Cargando...
Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer
The immunotherapy agent pembrolizumab has been approved for gastric cancer (GC) patients with recurrent or advanced disease who are PD-L1 positive. Mutations in the primary lesion may drive the expression of immune targets thereby priming the tumor to therapeutic sensitivity. In this study, we aimed...
Guardado en:
| Publicado en: | Front Pharmacol |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Frontiers Media S.A.
2019
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6331584/ https://ncbi.nlm.nih.gov/pubmed/30670970 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2018.01522 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|